share_log

和黃醫藥：自願性公告 - 和黃醫藥在中國啟動一項Menin抑制劑HMPL-506用於治療血液惡性腫瘤的I期臨床試驗

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

Hong Kong Stock Exchange ·  Jun 7 08:00
Summary by Futu AI
和黃醫藥（HUTCHMED）宣布於2024年5月31日在中國開始進行一項Menin抑制劑HMPL-506的I期臨床試驗，用於治療血液惡性腫瘤。這是一項多中心、開放標籤試驗，旨在評估HMPL-506的安全性、藥代動力學和療效，計劃招募至少60名患者。該研究由中國醫學科學院血液病醫院的王建祥醫生和魏輝醫生主導。HMPL-506是一種針對menin蛋白的口服小分子抑制劑，目前全球尚無menin抑制劑獲批上市。和黃醫藥保留HMPL-506在全球的所有權利。公司是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三款藥物在中國上市，其中一款也在美國上市。
和黃醫藥（HUTCHMED）宣布於2024年5月31日在中國開始進行一項Menin抑制劑HMPL-506的I期臨床試驗，用於治療血液惡性腫瘤。這是一項多中心、開放標籤試驗，旨在評估HMPL-506的安全性、藥代動力學和療效，計劃招募至少60名患者。該研究由中國醫學科學院血液病醫院的王建祥醫生和魏輝醫生主導。HMPL-506是一種針對menin蛋白的口服小分子抑制劑，目前全球尚無menin抑制劑獲批上市。和黃醫藥保留HMPL-506在全球的所有權利。公司是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三款藥物在中國上市，其中一款也在美國上市。
Hutchmed announced the initiation of a phase I clinical trial for its Menin inhibitor, HMPL-506, in China on May 31, 2024. The drug will be used to treat hematologic malignancies. The study will be a multicenter, open-label trial that aims to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506. At least 60 patients will be enrolled in the trial. The study will be led by Drs. Jianxiang Wang and Hui Wei from the Hematology Hospital of CAMS. HMPL-506 is an orally administered small molecule inhibitor that targets the Menin protein. Currently, there are no Menin inhibitors approved for marketing worldwide. Hutchmed retains all rights to HMPL-506 globally. The company is a biomedical firm that specializes in cancer and immunological disease treatment, with three drugs already on the market in China, one of which is also marketed in the USA.
Hutchmed announced the initiation of a phase I clinical trial for its Menin inhibitor, HMPL-506, in China on May 31, 2024. The drug will be used to treat hematologic malignancies. The study will be a multicenter, open-label trial that aims to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506. At least 60 patients will be enrolled in the trial. The study will be led by Drs. Jianxiang Wang and Hui Wei from the Hematology Hospital of CAMS. HMPL-506 is an orally administered small molecule inhibitor that targets the Menin protein. Currently, there are no Menin inhibitors approved for marketing worldwide. Hutchmed retains all rights to HMPL-506 globally. The company is a biomedical firm that specializes in cancer and immunological disease treatment, with three drugs already on the market in China, one of which is also marketed in the USA.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.